Advances & Updates
Post Updates
Aug
14
PNOC FOUNDATION, A LEADING NON-PROFIT DEDICATED TO ACCELERATING TREATMENTS FOR THE DEADLIEST CHILDHOOD BRAIN CANCERS, APPLAUDS THE U.S. FDA APPROVAL OF ONC201 (DORDAVIPRONE, NOW MODEYSO™) AS THE FIRST AND ONLY TREATMENT FOR RECURRENT H3 K27M-MUTANT DIFFUSE MIDLINE GLIOMA
ONC201 FDA approval for diffuse midline glioma - August 14, 2025
Media Release
Pre-clinical studies by PNOC’s DMG Working Group members contributed...
Oct
09
Pediatric Neuro-Oncology Consortium Partnership Receives Prestigious ARPA-H Multi-Million Dollar Grant for Groundbreaking RADIANT Project, to Rapidly Advance Treatments for Children With Brain Tumors
FOR IMMEDIATE RELEASE
SAN FRANCISCO, October 9, 2024 – The Pediatric Neuro-Oncology...
Nov
20
PNOC PUBLICATION!
PNOC001: Phase II Study of Everolimus For Recurrent or Progressive Low-Grade Gliomas in Children
...
Feb
03
Machine learning to identify LGG subgroups
Our Imaging working group looks at how an unsupervised machine learning approach could review and...
Connect with PNOC
Collaboration is a key part of PNOC’s values and our success. We collaborate with individuals, hospitals, research institutions, patients and families – with anyone. Contact us if you have an idea or question, or if you would like to learn more about collaborating with us.